EPA:ALBIO - Euronext Paris - Matif - FR0011005933 - Common Stock - Currency: EUR
EPA:ALBIO (6/18/2025, 7:00:00 PM)
1.245
+0.05 (+3.75%)
The current stock price of ALBIO.PA is 1.245 EUR. In the past month the price decreased by -4.96%. In the past year, price decreased by -62.67%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABL.DE | ABBOTT LABORATORIES | 27.79 | 200.67B | ||
1ISRG.MI | INTUITIVE SURGICAL INC | 67.85 | 161.49B | ||
IUI1.DE | INTUITIVE SURGICAL INC | 67.09 | 159.68B | ||
BSX.DE | BOSTON SCIENTIFIC CORP | 37.53 | 130.49B | ||
2M6.DE | MEDTRONIC PLC | 15.66 | 96.00B | ||
SHL.DE | SIEMENS HEALTHINEERS AG | 19.89 | 50.71B | ||
BOX.DE | BECTON DICKINSON AND CO | 12.08 | 42.38B | ||
EWL.DE | EDWARDS LIFESCIENCES CORP | 28.38 | 37.62B | ||
DC4.DE | DEXCOM INC | 49.43 | 27.71B | ||
1PHIA.MI | KONINKLIJKE PHILIPS NV | 14.18 | 18.39B | ||
PHI1.DE | KONINKLIJKE PHILIPS NV | 14.08 | 18.27B | ||
PHIA.AS | KONINKLIJKE PHILIPS NV | 13.87 | 17.99B |
Biosynex SA engages in the provision of development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est and currently employs 521 full-time employees. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.
BIOSYNEX
22 Boulevard Sebastien Brant
Illkirch-Graffenstaden GRAND EST FR
Employees: 521
Phone: 33388787887
The current stock price of ALBIO.PA is 1.245 EUR. The price increased by 3.75% in the last trading session.
The exchange symbol of BIOSYNEX is ALBIO and it is listed on the Euronext Paris - Matif exchange.
ALBIO.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALBIO.PA and the average price target is 12.85 EUR. This implies a price increase of 932.29% is expected in the next year compared to the current price of 1.245. Check the BIOSYNEX stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BIOSYNEX (ALBIO.PA) has a market capitalization of 23.34M EUR. This makes ALBIO.PA a Nano Cap stock.
BIOSYNEX (ALBIO.PA) currently has 521 employees.
BIOSYNEX (ALBIO.PA) has a resistance level at 1.26. Check the full technical report for a detailed analysis of ALBIO.PA support and resistance levels.
The Revenue of BIOSYNEX (ALBIO.PA) is expected to grow by 15.05% in the next year. Check the estimates tab for more information on the ALBIO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALBIO.PA does not pay a dividend.
BIOSYNEX (ALBIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.37).
ChartMill assigns a fundamental rating of 2 / 10 to ALBIO.PA. ALBIO.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ALBIO.PA reported a non-GAAP Earnings per Share(EPS) of -3.37. The EPS decreased by -12.27% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -22.24% | ||
ROE | -53.75% | ||
Debt/Equity | 0.19 |
ChartMill assigns a Buy % Consensus number of 87% to ALBIO.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 475% and a revenue growth 15.05% for ALBIO.PA